These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 27725524)

  • 1. Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group.
    Aoki T; Arakawa Y; Ueba T; Oda M; Nishida N; Akiyama Y; Tsukahara T; Iwasaki K; Mikuni N; Miyamoto S
    Neurol Med Chir (Tokyo); 2017 Jan; 57(1):17-27. PubMed ID: 27725524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the clinical efficacy of temozolomide (TMZ) versus nimustine (ACNU)-based chemotherapy in newly diagnosed glioblastoma.
    Wang Y; Chen X; Zhang Z; Li S; Chen B; Wu C; Wang L; Zhang X; Wang J; Chen L; Jiang T
    Neurosurg Rev; 2014 Jan; 37(1):73-8. PubMed ID: 23912878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
    Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
    Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ACNU-based chemotherapy for recurrent glioma in the temozolomide era.
    Happold C; Roth P; Wick W; Steinbach JP; Linnebank M; Weller M; Eisele G
    J Neurooncol; 2009 Mar; 92(1):45-8. PubMed ID: 18987781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.
    Chinot OL; Honore S; Dufour H; Barrie M; Figarella-Branger D; Muracciole X; Braguer D; Martin PM; Grisoli F
    J Clin Oncol; 2001 May; 19(9):2449-55. PubMed ID: 11331324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study.
    Brandes AA; Ermani M; Basso U; Amistà P; Berti F; Scienza R; Rotilio A; Pinna G; Gardiman M; Monfardini S
    Ann Oncol; 2001 Feb; 12(2):255-7. PubMed ID: 11300334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The outcomes of concomitant radiation plus temozolomide followed by adjuvant temozolomide for newly diagnosed high grade gliomas: the preliminary results of single center prospective study.
    Shawky H; Abo Hamar AH; Galal S; Zakaria F; El-Shorbagy D
    J Egypt Natl Canc Inst; 2009 Jun; 21(2):107-19. PubMed ID: 21057562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study.
    Taal W; Segers-van Rijn JM; Kros JM; van Heuvel I; van der Rijt CC; Bromberg JE; Sillevis Smitt PA; van den Bent MJ
    J Neurooncol; 2012 May; 108(1):195-200. PubMed ID: 22396071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma.
    Weller M; Müller B; Koch R; Bamberg M; Krauseneck P;
    J Clin Oncol; 2003 Sep; 21(17):3276-84. PubMed ID: 12947063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas.
    Minniti G; Scaringi C; De Sanctis V; Lanzetta G; Falco T; Di Stefano D; Esposito V; Enrici RM
    J Neurooncol; 2013 Jan; 111(2):187-94. PubMed ID: 23129347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center.
    Galldiks N; Berhorn T; Blau T; Dunkl V; Fink GR; Schroeter M
    J Neurooncol; 2013 Apr; 112(2):209-15. PubMed ID: 23299464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary hematological malignancies associated with temozolomide in patients with glioma.
    Momota H; Narita Y; Miyakita Y; Shibui S
    Neuro Oncol; 2013 Oct; 15(10):1445-50. PubMed ID: 23519741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Favourable result for temozolomide in recurrent high-grade glioma].
    Taal W; van der Rijt CD; Sillevis Smitt PA; Kros JM; van Heuvel I; Enting RH; van den Bent MJ
    Ned Tijdschr Geneeskd; 2005 Jun; 149(25):1393-9. PubMed ID: 15997692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.
    Chang SM; Prados MD; Yung WK; Fine H; Junck L; Greenberg H; Robins HI; Mehta M; Fink KL; Jaeckle KA; Kuhn J; Hess K; Schold C
    Cancer; 2004 Apr; 100(8):1712-6. PubMed ID: 15073861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temozolomide in paediatric high-grade glioma: a key for combination therapy?
    Verschuur AC; Grill J; Lelouch-Tubiana A; Couanet D; Kalifa C; Vassal G
    Br J Cancer; 2004 Aug; 91(3):425-9. PubMed ID: 15266331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas.
    Khan RB; Raizer JJ; Malkin MG; Bazylewicz KA; Abrey LE
    Neuro Oncol; 2002 Jan; 4(1):39-43. PubMed ID: 11772431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
    Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
    Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium.
    Everaert E; Neyns B; Joosens E; Strauven T; Branle F; Menten J
    J Neurooncol; 2004 Oct; 70(1):37-48. PubMed ID: 15527106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305).
    Shibui S; Narita Y; Mizusawa J; Beppu T; Ogasawara K; Sawamura Y; Kobayashi H; Nishikawa R; Mishima K; Muragaki Y; Maruyama T; Kuratsu J; Nakamura H; Kochi M; Minamida Y; Yamaki T; Kumabe T; Tominaga T; Kayama T; Sakurada K; Nagane M; Kobayashi K; Nakamura H; Ito T; Yazaki T; Sasaki H; Tanaka K; Takahashi H; Asai A; Todo T; Wakabayashi T; Takahashi J; Takano S; Fujimaki T; Sumi M; Miyakita Y; Nakazato Y; Sato A; Fukuda H; Nomura K
    Cancer Chemother Pharmacol; 2013 Feb; 71(2):511-21. PubMed ID: 23228988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.